Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SiriusXM Reaffirms FY22 Guidance

2022 GUIDANCE The company continues to expect positive full-year 2022 self-pay net subscriber additions and reiterated 2022 guidance for revenue, adjusted EBITDA, and free cash flow as follows: Total
byBenzinga Newsdesk
November 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

2022 GUIDANCE

The company continues to expect positive full-year 2022 self-pay net subscriber additions and reiterated 2022 guidance for revenue, adjusted EBITDA, and free cash flow as follows:

  • Total revenue of approximately $9.0 billion,
  • Adjusted EBITDA of approximately $2.8 billion, and
  • Free cash flow of approximately $1.55 billion.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

GSK Plc Announces The CHMP Of The EMA Has Adopted A Positive Opinion Recommending Approval Of Momelotinib For The Treatment Of Disease-related Splenomegaly Or Symptoms In Adult Patients With Moderate To Severe Anaemia

By Benzinga Newsdesk
November 13, 10:13 AM
GSK plc (NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with moderate to severe anaemia

GSK